Rapt Therapeutics Hits New 52-Week High

Analysts Debate Whether the Biotech Stock Is Still a Buy

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Shares of Rapt Therapeutics (NASDAQ:RAPT) reached a new 52-week high of $58.00 on Monday, continuing the biotech company's strong performance. However, analysts are divided on whether the stock is still a buy at current levels, with some downgrading it to a 'hold' rating.

Why it matters

Rapt Therapeutics is a clinical-stage biotech company developing novel treatments for autoimmune and allergic diseases. The company's stock price surge indicates growing investor confidence in its pipeline, but the mixed analyst ratings suggest uncertainty about the stock's future upside potential.

The details

Rapt Therapeutics' lead asset, RPT193, is an oral antagonist of the CCR4 receptor that is currently in clinical trials for atopic dermatitis and allergic asthma. The company has seen its stock price rise steadily in recent months, with the latest 52-week high representing a significant milestone. However, several analysts have downgraded the stock to 'hold' ratings, citing valuation concerns and a lack of near-term catalysts.

  • Rapt Therapeutics shares reached a new 52-week high of $58.00 on Monday, March 2, 2026.

The players

Rapt Therapeutics

A clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Rapt Therapeutics' stock surge highlights the potential of its pipeline, but the mixed analyst views suggest investors should closely monitor the company's progress and future catalysts before making investment decisions.